Context:
Financial Statements:
| Column 1                                                                                             | Column 2   | Column 3      | Column 4   | Column 5        | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:-----------------------------------------------------------------------------------------------------|:-----------|:--------------|:-----------|:----------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                                      |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
|                                                                                                      |            | April 4, 2021 |            | January 3, 2021 |            |            |            |            |             |             |             |             |             |             |
| ASSETS                                                                                               |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                      |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents                                                                            |            | $             | 12,671     |                 |            | 13,985     |            |            |             |             |             |             |             |             |
| Marketable securities                                                                                |            | 11,948        |            |                 | 11,200     |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances for doubtful accounts and credit losses $270(2020, $293) |            | 14,938        |            |                 | 13,576     |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                                 |            | 9,952         |            |                 | 9,344      |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                           |            | 3,024         |            |                 | 3,132      |            |            |            |             |             |             |             |             |             |
|                                                                                                      |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                                 |            | 52,533        |            |                 | 51,237     |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                                |            | 46,430        |            |                 | 46,804     |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                       |            | (28,063)      |            |                 | (28,038)   |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                   |            | 18,367        |            |                 | 18,766     |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                      |            | 51,110        |            |                 | 53,402     |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                    |            | 35,688        |            |                 | 36,393     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                    |            | 8,321         |            |                 | 8,534      |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                         |            | 6,538         |            |                 | 6,562      |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                         |            | $             | 172,557    |                 |            | 174,894    |            |            |             |             |             |             |             |             |
| LIABILITIES AND SHAREHOLDERS’ EQUITY                                                                 |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                                 |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                              |            | $             | 3,350      |                 |            | 2,631      |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                     |            | 8,503         |            |                 | 9,505      |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                  |            | 13,223        |            |                 | 13,968     |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                              |            | 11,919        |            |                 | 11,513     |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                                |            | 2,060         |            |                 | 3,484      |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                     |            | 1,877         |            |                 | 1,392      |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                            |            | 40,932        |            |                 | 42,493     |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                              |            | 30,263        |            |                 | 32,635     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                    |            | 6,507         |            |                 | 7,214      |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                                |            | 10,512        |            |                 | 10,771     |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                     |            | 6,568         |            |                 | 6,559      |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                    |            | 11,941        |            |                 | 11,944     |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                    |            | $             | 106,723    |                 |            | 111,616    |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                              |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                                |            |               |            |                 |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares)   |            | $             | 3,120      |                 |            | 3,120      |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                               |            | (15,328)      |            |                 | (15,242)   |            |            |            |             |             |             |             |             |             |
| Retained earnings                                                                                    |            | 116,508       |            |                 | 113,890    |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (487,141,000and487,331,000shares)                       |            | 38,466        |            |                 | 38,490     |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                           |            | 65,834        |            |                 | 63,278     |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders' equity                                                           |            | $             | 172,557    |                 |            | 174,894    |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                  | Column 2   | Column 3                  | Column 4   | Column 5      | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:------------------------------------------------------------------------------------------|:-----------|:--------------------------|:-----------|:--------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | Fiscal Three Months Ended |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | April 4,2021              |            | March 29,2020 |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                              |            | $                         | 6,197      |               |            | 5,796      |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 |            | 1,894                     |            |               | 1,747      |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                  |            | 307                       |            |               | 263        |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                         |            | 14                        |            |               | 11         |            |            |            |             |             |             |             |             |             |
| Contingent consideration reversal                                                         |            | —                         |            |               | (983)      |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     |            | (580)                     |            |               | —          |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                    |            | (730)                     |            |               | 54         |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          |            | (13)                      |            |               | 22         |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                           |            | (1,604)                   |            |               | (812)      |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                   |            | (695)                     |            |               | (159)      |            |            |            |             |             |             |             |             |             |
| Decrease in accounts payable and accrued liabilities                                      |            | (2,336)                   |            |               | (2,523)    |            |            |            |             |             |             |             |             |             |
| Decrease in other current and non-current assets                                          |            | 2,522                     |            |               | 271        |            |            |            |             |             |             |             |             |             |
| Decrease in other current and non-current liabilities                                     |            | (902)                     |            |               | (329)      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| NET CASH FLOWS FROM OPERATING ACTIVITIES                                                  |            | 4,074                     |            |               | 3,358      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                |            | (677)                     |            |               | (625)      |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net (Note 10)                            |            | 603                       |            |               | 17         |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired (Note 10)                                              |            | —                         |            |               | (939)      |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                  |            | (5,994)                   |            |               | (2,064)    |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                      |            | 5,233                     |            |               | 1,544      |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | 751                       |            |               | 1,743      |            |            |            |             |             |             |             |             |             |
| Other (primarily licenses and milestones)                                                 |            | (101)                     |            |               | (257)      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY INVESTING ACTIVITIES                                                     |            | (185)                     |            |               | (581)      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                 |            | (2,659)                   |            |               | (2,505)    |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                |            | (1,438)                   |            |               | (1,711)    |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt                                                             |            | 23                        |            |               | 10         |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt                                                              |            | (475)                     |            |               | (18)       |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       |            | 1                         |            |               | —          |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                               |            | (1,001)                   |            |               | (11)       |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net |            | 236                       |            |               | 332        |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | 212                       |            |               | —          |            |            |            |             |             |             |             |             |             |
| Other                                                                                     |            | (24)                      |            |               | (412)      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY FINANCING ACTIVITIES                                                     |            | (5,125)                   |            |               | (4,315)    |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Effect of exchange rate changes on cash and cash equivalents                              |            | (78)                      |            |               | (237)      |            |            |            |             |             |             |             |             |             |
| Decrease in cash and cash equivalents                                                     |            | (1,314)                   |            |               | (1,775)    |            |            |            |             |             |             |             |             |             |
| Cash and Cash equivalents, beginning of period                                            |            | 13,985                    |            |               | 17,305     |            |            |            |             |             |             |             |             |             |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                                  |            | $                         | 12,671     |               |            | 15,530     |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Acquisitions                                                                              |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Fair value of assets acquired                                                             |            | $                         | —          |               |            | 1,136      |            |            |             |             |             |             |             |             |
| Fair value of liabilities assumed and noncontrolling interests                            |            | —                         |            |               | (197)      |            |            |            |             |             |             |             |             |             |
| Net cash paid for acquisitions                                                            |            | $                         | —          |               |            | 939        |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                       | Column 2   | Column 3                   | Column 4   | Column 5        | Column 6   | Column 7      | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:-----------------------------------------------|:-----------|:---------------------------|:-----------|:----------------|:-----------|:--------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | Fiscal First Quarter Ended |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | April 4,2021               |            | Percentto Sales |            | March 29,2020 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                    |            | $                          | 22,321     |                 |            | 100.0         | %          |                 | $           | 20,691      |             |             | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                          |            | 7,063                      |            |                 | 31.7       |               |            | 7,062           |             |             | 34.1        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                   |            | 15,258                     |            |                 | 68.3       |               |            | 13,629          |             |             | 65.9        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses |            | 5,432                      |            |                 | 24.3       |               |            | 5,203           |             |             | 25.1        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense               |            | 3,178                      |            |                 | 14.2       |               |            | 2,580           |             |             | 12.5        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                |            | (15)                       |            |                 | (0.1)      |               |            | (67)            |             |             | (0.3)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized   |            | 63                         |            |                 | 0.3        |               |            | 25              |             |             | 0.1         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                    |            | (882)                      |            |                 | (3.9)      |               |            | (679)           |             |             | (3.3)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                        |            | 53                         |            |                 | 0.2        |               |            | 58              |             |             | 0.3         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income  |            | 7,429                      |            |                 | 33.3       |               |            | 6,509           |             |             | 31.5        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 5)         |            | 1,232                      |            |                 | 5.5        |               |            | 713             |             |             | 3.5         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS                                   |            | $                          | 6,197      |                 |            | 27.8          | %          |                 | $           | 5,796       |             |             | 28.0        | %           |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS PER SHARE (Note 8)                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | $                          | 2.35       |                 |            |               |            | $               | 2.20        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | $                          | 2.32       |                 |            |               |            | $               | 2.17        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| AVG. SHARES OUTSTANDING                        |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | 2,631.6                    |            |                 |            |               | 2,633.7    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | 2,672.7                    |            |                 |            |               | 2,671.0    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The application is supported by positive results from the ongoing Phase 1b/2 CARTITUDE-1 study, investigating the safety and efficacy of cilta-cel.1,2 The latest results were presented at the American Society of Hematology (ASH) 2020 Annual Meeting. Clinical development is ongoing with patients enrolled globally in various studies, including sites in Europe, the United States of America, China and Japan.1,2 Despite advances in the treatment of multiple myeloma, there remains a high unmet need, especially for patients whose disease continues to progress, said Peter Lebowitz, M.D., PhD., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. Through our collaboration with Legend Biotech, we continue to expedite the development of cilta-cel with a focus and priority on the patients who may benefit from this novel immunotherapy in the future. CART therapy is a highly personalised treatment platform where a patients own T-cells are re-programmed to recognise and attack cancer cells.3 In early 2021, the EMA granted accelerated assessment for cilta-cel.4 Accelerated assessment is granted when a medicinal product is expected to be of major public health interest and a therapeutic innovation, and can significantly reduce the review timelines to evaluate an MAA.5 Janssen has been advancing the science of oncology for more than 30 years, and we see great opportunity in the area of cell therapy and through our innovative platforms, says Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. We are continuing to harness our deep scientific expertise in multiple myeloma as we look to advance therapeutic options, deepen clinical responses, and drive towards improved patient outcomes. Todays submission to the EMA epitomises how we strive to make a meaningful impact in the multiple myeloma landscape through advancing innovative treatments for patients, says Saskia De Haes, Vice President, EMEA Regulatory Affairs, Janssen R&D BE. We look forward to working in partnership with health authorities, as part of the accelerated assessment process, to support these patients by ensuring timely access to the latest therapeutic options. A Biologics License Application seeking approval of cilta-cel for the treatment of relapsed and/or refractory multiple myeloma is currently under review by the United States Food and Drug Administration.6 # ENDS # About CARTITUDE-1 CARTITUDE-1 (NCT03548207) is an ongoing Phase 1b/2, open-label, multicentre study evaluating the safety and efficacy of JNJ-68284528 (JNJ-4528) in adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy or are double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); have received a PI, IMiD and an anti-CD38 antibody.2 The primary objective of the Phase 1b portion of the study is to characterise the safety and confirm the dose of JNJ-68284528 (JNJ-4528), which was informed by the first-in-human study with LCAR-B38M CAR-T cells (LEGEND-2).2 The primary objective for the Phase 2 portion of the study is to evaluate the efficacy of JNJ-4528 (primary endpoint: overall response rate as defined by the International Myeloma Working Group response criteria).2 About Ciltacabtagene Autoleucel (cilta-cel) Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy for the treatment of patients with multiple myeloma. Cilta-cel is a differentiated CAR-T therapy with two BCMA-targeting single domain antibodies.1 CAR-T cells are an innovative approach to targeting cancer cells by harnessing the power of a patients own immune system. 7 BCMA is a protein that is highly expressed on myeloma cells.8 In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech to develop and commercialise cilta-cel.9 In May 2018, Janssen initiated a Phase 1b/2 CARTITUDE-1 trial (NCT03548207) to evaluate the efficacy and safety of cilta-cel in adults with relapsed and/or refractory multiple myeloma, informed by the LEGEND-2 study results.2,10 In 2019, cilta-cel was granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA).11 PRIME offers enhanced interaction and early dialogue with developers of promising medicines, to optimise drug development plans and speed up evaluation of cutting-edge, scientific advances that target a high unmet medical need.12 In 2020, the European Commission granted orphan designation for cilta-cel.13 About Multiple Myeloma Multiple myeloma (MM) is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive proliferation of plasma cells.14 In Europe, 50,918 people were diagnosed with MM in 2020, and more than 32,400 patients died.15 Around 50 percent of newly diagnosed patients do not reach five-year survival,16 and approximately 10 percent of patients with multiple myeloma will die within one year of diagnosis.17 Although treatment may result in remission, unfortunately, patients will most likely relapse as there is currently no cure.18 Refractory MM is when a patients disease progresses within 60 days of their last therapy.19 Relapsed cancer is when the disease has returned after a period of initial, partial or complete remission.20 While some patients with MM have no symptoms at all, others are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.21 Patients who relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, have poor prognoses and require new therapies for continued disease control.22 About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, were creating a future where disease is a thing of the past. Were the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA for our latest news. Janssen Pharmaceutica NV, Janssen R&D BE, and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Chinese News:
耶伦的“鹰派”言论“带崩”了周二的美股走势。当天，她火速发表了澄清言论，第二天，多位美联储官员也重申通胀可控，美股市场在周三终于“稳住了”，道指还创下盘中新高。抗疫方面也有大事，拜登政府宣布将放弃新冠疫苗的知识产权专利。三家疫苗巨头市值蒸发500亿，板块概念股中还有一只股票跌了16%。多位美联储官员重申通胀可控道指再创盘中新高 当地时间周二，耶伦的讲话引发了市场震荡，投资者对于通胀的担忧也愈发强烈。周二盘后耶伦澄清没有对美联储政策进行预测或建议，周三，美联储多位官员也开始发声，美股也“稳住了”，没有延续大幅下跌的走势。当地时间周三，美联储副主席克拉里达表示现在还不应该讨论缩减购债规模，而且美国经济距离目标还有很长的路要走。他还表示，周二美国财长耶伦已经表明了她没有对美联储的政策进行预测或提出建议。克拉里达还表示希望看到经济方面的实际进展，但美国经济目前还没有取得实质性进展。克拉里达认为，美国的实际失业率接近10%，就业人数仍比疫情爆发前少800万；在就业市场复苏之际，快速的经济增长是受欢迎的。同一天，芝加哥联储主席埃文斯表示，尽管政府为应对疫情推出了前所未有的财政支出计划，但美国的通货膨胀依然不太可能失控；如果就业目标达到，但平均通胀率没有达到2%，那么应该继续实行宽松政策。波士顿联储主席罗森伯格表示，今年通胀率上升是暂时的；最有可能的结果依然是通胀正常化，接近2%的目标；如果通胀出现问题，美联储有应对的工具。克利夫兰联储主席梅斯特称，即使通胀超过美联储的目标水平2%，也难以持续满足联储有关加息的利率指引要求。美联储对市场的安抚起了一定效果，美股三大股指周三整体呈现窄幅震荡的走势，未继续大幅下行。截至收盘，道琼斯指数涨0.29%，报34230.34点。纳斯达克指数跌0.37%，报13582.42点。标普500指数涨0.07%，报4167.59点。 道指还在盘中创下历史新高。拜登政府：将放弃新冠疫苗的知识产权专利 疫苗概念股下挫，最多跌了16% 美国终于表态将豁免新冠疫苗知识产权，疫苗概念股立马跌了.据央视，拜登政府当地时间5月5日发表一项决定，表示美国将放弃新冠肺炎疫苗的知识产权专利。美国贸易部部长戴琪(Katherine Tai)5日在一份声明中宣布了美国政府的这一决定。此前，美国制药商曾就此事进行了激烈的内部辩论和大力反击。戴琪表示，政府此举是为了尽快普及安全有效的疫苗，结束新冠肺炎疫情。她同时表示，美国政府将继续加强与私营部门和所有可能伙伴的合作，扩大疫苗的制造和分销，以及努力增加生产这些疫苗所需的原材料。美国此举有可能扩大新冠肺炎疫苗的全球供应，缩小富国和穷国之间的疫苗接种差距。美国白宫办公厅主任罗恩·克莱因(Ron Klain)2日曾表示，知识产权是全球新冠肺炎疫苗短缺问题的一部分，但更大的问题在于制造业。他说，白宫将在“未来几天”透露更多消息。据新华社，此前，世界卫生组织总干事谭德塞和英国前首相戈登·布朗于本月3日共同呼吁暂时豁免新冠疫苗知识产权。谭德塞在当天举行的线上记者会上说，过去两周全球报告的新增新冠确诊病例数比疫情开始后的头6个月加起来还要多；上周印度和巴西报告的新增感染病例数占全球半数以上，还有许多国家面临非常脆弱的局势。谭德塞表示，如果要为大多数成年人接种疫苗以实现群体免疫，需要的疫苗将大大超过现有数量；为提高疫苗产量，暂时豁免疫苗知识产权非常重要，而这并不是一个“慈善问题”。受美国表态将放弃新冠肺炎疫苗专利这一消息的影响，多支疫苗概念股下跌。Vaxart跌幅最大，收盘跌幅接近16%。 三家疫苗巨头市值蒸发500亿 Moderna跌超6%，市值蒸发43亿美元，约合280亿人民币。 Biotech跌超3%，市值蒸发15亿美元，约合97亿人民币。强生微跌0.42%，市值蒸发18.55亿美元，约合120亿人民币。周三，上述三家疫苗巨头市值蒸发76.55亿美元，约合497亿人民币。 辉瑞和阿斯利康逆势上涨，其中，阿斯利康为英国公司。这一通胀指标创13年新高 亿万富翁投资人警告加息或提前 即使耶伦紧急澄清，美联储多位官员也发声，部分关于通胀的指标还是创下了多年新高。当地时间周二，彭博大宗商品现货指数攀升至2011年以来的最高水平，创10年新高。当地时间周三，美国5年期盈亏平衡通胀率一举突破2.7%，创下2008年7月以来的最高水平，创13年新高；10年期盈亏平衡通胀率周三也涨至多年来高点。亿万富豪投资人Cooperman认为，不断上升的通货膨胀率或将迫使美联储提前至明年加息。当地时间周三，他在接受彭博专访时表示，“我猜美联储会对通胀感到惊讶，这会更难办。市场可能会对美联储在2022年的某个时候加息感到震惊，这也将是他们因通货膨胀而被迫做出的决策。”荷兰合作银行分析师Richard McGuire表示，盈亏平衡通胀率的上涨意味着市场还存在较强的不确定性，虽然政策决策者承诺通胀率上升只是暂时现象，但投资者还是对疫情后将面临的巨大通胀压力感到担忧。

Japanese News:
米国の医薬品・ヘルスケア大手、ジョンソン・エンド・ジョンソン（J&J）が発表した今年第1四半期（1〜3月期）の決算は、市場予想を上回る好調な利益を記録した。新型コロナウイルスのワクチンについては売上が1億ドルに達したが、安全性への懸念から米国内や南アフリカでは一時的に接種が見合わせられている状況だ。同社はまた、株主配当を増額すると発表した。 J&Jの新型コロナワクチンについては、米保健当局が接種を受けた女性6人に生じた血栓症状を調査するため、現在一時的な使用中止措置を取っている。南アフリカでも同様に接種が一旦停止されている。一方、同社は5月末までに米国内で1億回分の供給を計画しており、4月19日時点ですでに1700万回以上が提供済みである。 シティグループのアナリスト、ジョアン・ウェンシュ氏はリポート内で「ワクチンに対して複数の疑問や懸念点は生じているものの、J&J全体としての業績回復の勢いを阻害するものではない」と指摘した。 特別項目を除いた第1四半期の調整後1株当たり利益は2.59ドルとなり、リフィニティブ調査による市場予想平均（2.34ドル）を上回った。 同期の売上高は前年同期比で7.9％増加し、223億2000万ドルを記録した。こちらもアナリストの予測である219億8000万ドルを超える結果となった。 また、2021年通期の調整後1株利益については、9.42～9.57ドルとの見通しを示した（前回予測は9.40～9.60ドル）。 さらに四半期配当についても、1株当たり1.01ドルから1.06ドルへと引き上げる方針を発表した。

Spanish News:
La multinacional farmacéutica Johnson & Johnson registró en el primer trimestre ventas notablemente superiores a las estimaciones del mercado, mientras aguarda una resolución por parte de las autoridades sanitarias estadounidenses acerca del posible reinicio del uso de su vacuna contra el COVID-19. En cuanto a las previsiones anuales, la empresa ajustó ligeramente sus expectativas para 2021, ubicando ahora la ganancia ajustada por acción entre 9,42 y 9,57 dólares, una leve modificación frente al rango de 9,40 a 9,60 dólares previsto inicialmente en enero. Esta nueva estimación está alineada con el consenso de Wall Street, situado en 9,50 dólares por acción. Durante el primer trimestre, la compañía obtuvo ingresos totales por 22.320 millones de dólares, superando claramente la estimación promedio de analistas, que ascendía a 21.980 millones de dólares. La semana anterior, las autoridades sanitarias estadounidenses decidieron suspender temporalmente la administración de la vacuna contra COVID-19 desarrollada por Johnson & Johnson, después de que seis mujeres experimentaran raros pero graves casos de coágulos cerebrales tras recibir la dosis. Un comité de expertos médicos analizará próximamente estos eventos adversos para determinar si se levanta la suspensión. Hasta mediados de abril, aproximadamente 7,7 millones de ciudadanos estadounidenses habían recibido esta vacuna. Aunque en enero el director financiero Joseph Wolk anticipó a Bloomberg que la empresa probablemente ofrecería una previsión de ventas anuales de la vacuna en abril, Johnson & Johnson decidió no emitir aún una estimación formal de ingresos para este producto debido al actual contexto de incertidumbre. Sin embargo, la compañía sí comunicó ingresos de 100 millones de dólares en Estados Unidos derivados de la vacuna durante el primer trimestre. Actualmente, J&J distribuye la vacuna bajo un modelo sin fines de lucro, con un precio máximo de aproximadamente 10 dólares por dosis, mientras dure la pandemia. Johnson & Johnson continúa defendiendo el balance positivo entre beneficios y riesgos de su vacuna. Se espera que sus ejecutivos aborden en detalle el tema durante la conferencia telefónica con inversores programada para esta mañana. Por otro lado, la empresa anunció un aumento del 5% en su dividendo trimestral, que pasará de 1,01 a 1,06 dólares por acción. En las operaciones previas a la apertura del mercado, las acciones mostraban un leve descenso del 0,3%, ubicándose en 162,21 dólares. Desde inicios de año hasta el cierre del día anterior, las acciones acumulaban una ganancia del 3,4%. En relación con las diferentes unidades del negocio, la división farmacéutica continuó siendo clave, representando más del 50% de los ingresos totales. Sus ventas aumentaron un 10% interanual, alcanzando 12.200 millones de dólares durante este período. Dentro de este segmento destacó especialmente el medicamento inmunoterapéutico Stelara, cuyas ventas crecieron un 18%, generando ingresos de 2.200 millones de dólares. Aunque el impacto de la pandemia afectó inicialmente al segmento de dispositivos médicos debido al aplazamiento de cirugías y procedimientos hospitalarios, la división registró una notable recuperación en este trimestre, incrementando sus ventas un 11% respecto al año previo, hasta llegar a los 6.580 millones de dólares. Sin embargo, la división de productos de consumo registró una caída del 2,3%, alcanzando ventas por 3.540 millones de dólares. Johnson & Johnson atribuyó este retroceso al fuerte contraste con el primer trimestre de 2020, cuando la pandemia generó un aumento significativo en la demanda de productos básicos como Tylenol y Listerine, debido al abastecimiento preventivo por parte de los consumidores. En términos globales, la farmacéutica alcanzó en el primer trimestre una ganancia ajustada por acción de 2,59 dólares, frente a los 2,30 dólares del mismo período del año anterior.

Greek News:
Εν μέσω αυξανόμενων διεθνών ανησυχιών σχετικά με σπάνια περιστατικά θρομβώσεων, αρκετές χώρες επανεξετάζουν τη χρήση του εμβολίου της Johnson & Johnson κατά του Covid-19, προκαλώντας πιθανές επιπτώσεις στην πορεία των εμβολιαστικών προγραμμάτων και στις οικονομικές προβλέψεις. Συγκεκριμένα, η Δανία απέσυρε το εμβόλιο από το εθνικό της εμβολιαστικό πρόγραμμα, εκτιμώντας ότι οι πιθανοί κίνδυνοι είναι περισσότεροι από τις αναμενόμενες οφειλές. Η απόφαση αυτή εκτιμάτε ότι θα καθυστερήσει τις εμβολιαστικές προσπάθειες κατά περίπου τέσσερις εβδομάδες και ως αποτέλεσμα να επηρεάσει την εθνική οικονομική δραστηριότητα. Ωστόσο, οι αρχές δεν απέκλεισαν την επανεξέταση της στάσης τους, εφόσον υπάρξουν νέα επιστημονικά δεδομένα. Παρομοίως στον Καναδά, η εθνική επιστημονική επιτροπή συνέστησε τη χρήση του συγκεκριμένου εμβολίου μόνο σε άτομα άνω των 30 ετών, ενώ η Γαλλία έχει περιορίσει τη χρήση του σε πολίτες άνω των 55 ετών. Οι διαφοροποιημένες εθνικές προσεγγίσεις αναδεικνύουν την αβεβαιότητα που περιβάλλει την αξιοποίηση του συγκεκριμένου εμβολίου και ενδέχεται να επηρεάσουν τους ρυθμούς επίτευξης ανοσίας, με άμεσες συνέπειες για την οικονομική ανάκαμψη της εκάστοτε χώρας. Παράλληλα, οι εξελίξεις αυτές δημιουργούν νέες παραμέτρους στον σχεδιασμό της υγειονομικής πολιτικής και της διαχείρισης των αποθεμάτων εμβολίων σε παγκόσμιο επίπεδο.

Question:
What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer: Johnson & Johnson's revenue grew from $20,691 million in Q1 2020 to $22,321 million in Q1 2021, representing 7.9% year-over-year growth. The company's sales exceeded analyst expectations of $21.98 billion. Revenue growth was driven by all three business segments: pharmaceuticals (+10%), medical devices (+11%), and consumer products (-2.3%). The strong pharmaceutical division contributed over 50% of total revenues.
News Evidence: "同期の売上高は前年同期比で7.9％増加し、223億2000万ドルを記録した" (Japanese); "la compañía obtuvo ingresos totales por 22.320 millones de dólares, superando claramente la estimación promedio de analistas, que ascendía a 21.980 millones de dólares" (Spanish); "During el primer trimestre, la división farmacéutica continuó siendo clave, representando más del 50% de los ingresos totales" (Spanish)

Question: How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Answer: J&J's balance sheet shows current assets of $52,533 million as of April 4, 2021, compared to $51,237 million at January 3, 2021. The company maintains strong liquidity with $12,671 million in cash and equivalents plus $11,948 million in marketable securities. The total liability to equity ratio is 1.62 (calculated as $106,723/$65,834), indicating moderate leverage. The company's financial position appears solid with substantial liquid assets.
News Evidence: None

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer: None
News Evidence: None

Question: What is the company's R&D ratio (R&D divided by revenue)? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Answer: Johnson & Johnson's R&D ratio for Q1 2021 was 14.2% (R&D expense of $3,178 million divided by sales of $22,321 million). This represents an increase from 12.5% in Q1 2020, indicating the company is investing more in research and development relative to revenue.
News Evidence: None